590 filings
Page 7 of 30
8-K
vi09amo
14 Jun 21
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
7:32am
8-K
d5v6zj
26 May 21
9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating
8:33am
8-K
x1vw2xme0h r06v
17 May 21
Other Events
7:36am
4
uo9dnszi43 1k6
13 May 21
Change in insider ownership
6:34pm
8-K
lo563jw91 j3ttu
13 May 21
9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021
7:47am
DEFA14A
a1g7c w2dlngb75c0
12 May 21
Additional proxy soliciting materials
7:32am
8-K
l0ddn3xr36c 34xqn3c
21 Apr 21
9 Meters Biopharma, Inc. to Participate in the Truist Securities
7:33am
8-K
4o8or
19 Apr 21
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters’ Program in Short Bowel Syndrome
7:32am
8-K
nh1e4jn4jnkek
12 Apr 21
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters’ Phase 3 CeDLara Study
7:32am
SC 13D/A
vtvltq
7 Apr 21
9 METERS BIOPHARMA / OrbiMed Israel BioFund GP Limited Partnership ownership change
4:46pm
4
5s3yt0g2
6 Apr 21
9 METERS BIOPHARMA / Mark A Sirgo ownership change
4:19pm
4
d215m
6 Apr 21
9 METERS BIOPHARMA / John Temperato ownership change
4:16pm
4
vqh1t
6 Apr 21
9 METERS BIOPHARMA / Edward J Sitar ownership change
4:15pm
8-K
hb6hcn
5 Apr 21
9 Meters Biopharma Announces Proposed Public Offering of Common Stock
4:26pm
424B5
08qgyu eumqn2lv
31 Mar 21
Prospectus supplement for primary offering
4:40pm
424B5
wvt1scc rrqna22i
30 Mar 21
Prospectus supplement for primary offering
5:01pm
SC 13D/A
fx4a8 h70h
25 Mar 21
9 METERS BIOPHARMA / OrbiMed Israel BioFund GP Limited Partnership ownership change
12:00am